1. Alberts MJ, Bertels CD, Dawson DV. An analysis of the time of presentation after stroke. JAMA 1990;263:65-68.
2. Langhorne P, Williams BO, Gilchrist W, Howle K. Do stroke units save lives? Lancet 1993;342:395-398.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study(ECASS). JAMA 1995;274:1017-1025.
5. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Thies W, et al. Guidelines for thrombolytic therapy for acute stroke : a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996;94:1167-1174.
6. International Stroke Trial Collaborative Group. The International Stroke Trial (IST) : a randomized trial of aspirine, subcutaneous heparin, both, or neither among 10,435 patients with acute ischemic stroke. Lancet 1997;349:1569-1581.
7. CAST : randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997;349:1641-1649.
8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
9. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
10. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ. Low dose heparin as a prophylaxis against deep vein thrombosis after acute stroke. Lancet 1977;2:800-801.
11. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Gent M, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-526.
12. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Wong A, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
13. The Publication Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke : a randomized controlled trial. JAMA 1998;279:1265-1267.
14. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischemc stroke and atrial fibrillation : a double blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000;355:1205-1210.
15. The European Ad Hoc Consensus Group. Optimizing intensive care in stroke : a European perspective. Cerebrovasc Dis 1997;7:113-128.
16. Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Olsen TS, et al. Body temperature in acute stroke : relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996;347:422-425.